Advertisement

Monitoring of Effectiveness of Prostaglandin Therapy in Humans

  • H. Sinzinger
Conference paper

Abstract

Since the discovery of prostaglandin I2 (PGI2) in 1976 and the reports that this endogenously produced substance is diminished in atherosclerosis, it has been widely used together with PGE1 for the treatment of human atherosclerosis. Most of the therapeutic regimes were based upon Szczeklik’s report [10] stating that a 72-h continuous intra-arterial infusion results in a clinical benefit in patients suffering from peripheral vascular disease. Owing to the preliminary success prostaglandins were handled with exaggerated enthusiasm without any search for a better therapeutic scheme or for methods allowing the verification of the effect of therapeutic intervention.

Keywords

Platelet Deposition Human Atherosclerotic Lesion Autologous Platelet Citrate Dextrose Arteriosclerosis Obliterans 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fitscha P, Kaliman J, Sinzinger H (1985) Gamma-camera imaging after autologous human platelet labeling with 111In-oxine sulfate: a key for assessing the efficacy of prostacyclin treatment in active atherosclerosis? In: Schrör K (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Karger, Basel, pp 358–364Google Scholar
  2. 2.
    Höfer R, Sinzinger H. Leithner C, Schwarz M, Bergmann H (1981) Experiences with 111In-oxine labelling of autologous platelets in follow-up studies of human kidney transplants. Nucl Med Commun 2: 120Google Scholar
  3. 3.
    Sinzinger H, Silberbauer K, Horsch AK, Gall A (1981) Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease — a rebound phenomenon? Prostaglandins 21: 49–51PubMedCrossRefGoogle Scholar
  4. 4.
    Sinzinger H, Reiter S (1984) The intrafusion platelet rebound and following PGEX-infusion is faster and more intensive than that with PGI2. Prostaglandins Leukotrienes and Medicine 13: 281–288CrossRefGoogle Scholar
  5. 5.
    Sinzinger H, Fitscha P (1984) Epoprostenol and platelet deposition in atherosclerosis. Lancet 1: 905–906PubMedCrossRefGoogle Scholar
  6. 6.
    Sinzinger H, O’Grady J, Fitscha P (1985) Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo. Lancet (submitted)Google Scholar
  7. 7.
    Sinzinger H, Fitscha P, Kaliman J, Silberbauer K, O’Grady J (1985) Development of optimal infusion regimes for epoprostenol using radiolabeled platelet uptake over atherosclerotic lesions in man. N Engl J Med (submitted)Google Scholar
  8. 8.
    Sinzinger H, O’Grady J, Fitscha P (1985) Platelet deposition on human atherosclerotic lesions is decreased by low dose aspirin in combination with dipyridamole. N Engl J Med (submitted)Google Scholar
  9. 9.
    Sinzinger H, Fitscha P (1984) Scintigraphic detection of femoral artery atherosclerosis with 111-indium-labeled autologous platelets. VASA 13: 350–353PubMedGoogle Scholar
  10. 10.
    Szczeklik A, Nizankowski R, Skawinski S, Szczeklik G, Gluszko P, Gryglewski RJ (1979) Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1: 1111–1114PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1987

Authors and Affiliations

  • H. Sinzinger
    • 1
    • 2
  1. 1.Department of Nuclear MedicineUniversity of ViennaAustria
  2. 2.Atherosclerosis Research Group (ASF)ViennaAustria

Personalised recommendations